Pfizer Tasocitinib meets primary endpoint in Phase 2 study
Tasocitinib is a Janus Kinase (JAK) inhibitor. It is believed that the JAK pathways play an important role in the psoriasis disease cascade. In the trial, at week
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The award is expected to fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen’s tetravalent dengue vaccine, DENVax delivered with PharmaJet’s convenient needle-free injection device. Inviragen
ProVation MD replaces dictation and transcription and allows physicians to document procedures at the point of care, streamlines the coding and billing process and enhances compliance by producing